In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Darren Carroll promoted to senior VP at Lilly

This article was originally published in Scrip

Executive Summary

Lilly has named current vice-president of corporate business development, Darren J Carroll, senior vice-president of corporate BD. Mr Carroll has been at Lilly for 18-years and was the driver behind the company's Capital Funds Portfolio strategy with several venture capital fund managers, which has led to the creation of 11 new companies so far, including Artaeus, which Lilly acquired in January 2014. He will report to Derica Rice, Lilly's executive vice-president of global services and CFO. 

You may also be interested in...



First Vaccine Approval For Janssen With Two-Dose Ebola Prophylactic

The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.

COVID-19 Vaccine Expectations Are Ambitious Not Impossible

Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D

Shorla Pharma Sees Opportunity In Re-Innovated Oncology Drugs

Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.

Topics

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel